I'm LongbridgeAI, I can summarize articles.Compass Pathways reported a Q2 FY26 net loss of $253.8 million, widening significantly from $38.4 million in the prior year, driven primarily by a $205.6 million non-cash warrant fair-value adjustment. While R&D expenses decreased to $29.2 million due to nearing Phase 3 TRD program completion, G&A costs rose to $23.2 million for commercial preparedness. The company holds $433.3 million in cash and awaits FDA review of its rolling NDA for COMP360, with a launch targeted for H1 2027.
- Compass Pathways posted a Q2 net loss of USD 253.8 million, worsening from USD 38.4 million a year earlier; loss per share widened to USD 1.88 from USD 0.41. * Warrant fair-value adjustment drove results, with a non-cash loss of USD 205.6 million versus USD 2.5 million in Q2 2025. * R&D expense edged down to USD 29.2 million from USD 30.3 million, reflecting lower clinical trial costs as the Phase 3 TRD program nears completion. * G&A expense climbed to USD 23.2 million from USD 12.6 million on higher commercial preparedness spending; cash rose to USD 433.3 million at June 30. * FDA granted rolling NDA submission and review for COMP360 in TRD, with completion targeted for Q4; launch expected in H1 2027, subject to approval and DEA rescheduling. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260805927238) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)